Advanced Therapies Integrates 2023: On Demand Videos
DEVELOPMENT, MANUFACTURE
& IMPLEMENTATION
Exploring the challenges in the journey to widespread adoption of ATMPs, from efficient manufacturing to streamlined NHS implementation.
Welcome and Fireside Chat
Welcome & Opening Remarks
Sally Ann Forsyth OBE | Chief Executive Officer | Stevenage Bioscience Catalyst
Fireside Chat 1: Getting C> to the people who need them
With rapid innovations in the cell and gene therapy arena, how do we integrate breakthrough treatments into routine practice to ensure seamless access for the people living with potentially treatable conditions? How will improved access benefit both people receiving treatments and the wider community?
Speakers Include:
Samantha Barber | Chief Executive | Gene People
Neil Watson | Co-Director | Northern Alliance Advanced Therapies Treatment Centre
Interviewed By:
Nicola Redfern | Consultant | NJ Redfern Ltd
Fireside Chat 2: The Future of the ATMP CDMO Market: Challenges and Opportunities
In this interview, we explore the current and future trends of the advanced therapy medicinal products (ATMP) CDMO (Contract Development and Manufacturing) market. We discuss the impact of COVID-19, the basis of competition, the drivers of cost reduction, and the best practices for developing ATMPs at scale.
Speakers Include:
Robert Panting | General Manager ATMP | Rentschler Biopharma
Interviewed By:
Matthew Durdy | Chief Executive Officer | Cell and Gene Therapy Catapult
Session 1
The right place at the right time
Manufacturing ATMPs requires advanced skills and expensive equipment. Does the UK system of science parks and innovation hubs support access to facilities and expertise?
FACILITATED BY
Sally Ann Forsyth OBE | Chief Executive Officer | Stevenage Bioscience Catalyst
PANELLISTS
Katy Newton | Senior Vice President immunology and Process Development | Achilles Therapeutics
Ketki Vispute | Associate Director, CAR-T manufacturing and Operations | Autolus
Ellie Junod | Investment Manager, Life Sciences | UBS
Philip Probert | Biologics Technology Lead | CPI
Tom Pike | Deputy Chief Executive Officer & Strategic Director | Stevenage Borough Council
Session 2
Can we make them cheaper?
Advanced Therapies offer huge benefits, but often at a huge price tag. How can we improve standardisation and reduce the costs of manufacturing?
FACILITATED BY
Stephen Blatcher | Head of MedTech | Team Consulting
PANELLISTS
Gaurav Venkataraman | Cofounder and Chief Executive Officer | Trisk Bio
Terri Gaskell | Chief Technical Officer | Rinri Therapeutics Ltd
Michael Baker | Senior Director, Viral Gene Therapy | FUJIFILM Diosynth Biotechnologies
Antoine Espinet | Co Founder & Chief Executive Officer | MicrofluidX
James Rutley | Head of our Business Development | Autolomous
Session 3
You’re the Cell to my Gene
The right partner can help you ensure ATMP quality & safety and overcome financial & regulatory hurdles. How do you find the right cell & gene outsourcing partner, and how do you ensure this partnership is productive to both parties?
FACILITATED BY
James Fry | Partner and Head of Life Sciences | Mills & Reeve
PANELLISTS
Kella Kapnisi | Project Manager, Senior Consultant | Team Consulting
Aimee Tyler | Clinical Account Manager | Miltenyi Biotec
Mark Cunningham | Head of Operations | NATA – Nucleic Acid Therapy Accelerator
Joe Healey | Chief Executive Officer and Co-Founder | NanoSyrinx
Session 4
Not so rare after all
The first success of ATMPs has been seen in rare and complex diseases, but they have potential to go much further. How far and how fast can Advanced Therapies transition into more mainstream indications?
FACILITATED BY
William Scott | Scientific Director, Transplant Regenerative Medicine | Newcastle University Medical School
PANELLISTS
Dominic Schmidt | General Partner | Advent Life Sciences
Stefanos Theoharis | Chief Business Officer | Kiji Therapeutics
Steve Kappenthuler | Chief Business Officer and Co-founder | Muvon Therapeutics
Simon Chandler | Chief Executive Officer | Rinri Therapeutics
Fotios Sampaziotis | Group Leader | University of Cambridge
Session 5
I got skills, they’re multiplying
Between 2021 and 2026, the UK advanced therapy and bioprocessing workforce is predicted to increase by over 100%. How can the industry and government work together to attract and retain the skills to support this growth?
FACILITATED BY
Ian Parnham | Skills Programme Lead | Cell and Gene Therapy Catapult
PANELLISTS
Bakul Gupta | Co-Founder | Deliver Biosciences
Dharmesh Vara | EMEA Field Application Specialist Leader | Cytiva
Rebecca Street | Head of Digital Operations | RoslinCT
James Kusena | Vice President of Operations | MicrofluidX
Anji Miller | Programme Director Translational Fellowships Skills Lead, Innovation hubs for Gene Therapies Senior Business Manager, LifeArc | LifeArc
Alessia Errico | Associate Director Search & Evaluation and Entrepreneurial Programmes Lead | Cancer Research Horizons